Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: Impact on rejection, graft function, and long-term outcome

Transplantation

Volumn 92, Issue 9, 2011, Pages 1039-1043

  Bazerbachi, Fateh ^a   Selzner, Markus ^a   Boehnert, Markus U ^a   Marquez, Max A ^a   Norgate, Andrea ^a   McGilvray, Ian D ^a   Schiff, Jeffrey ^a   Cattral, Mark S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Basiliximab; Induction therapy; Simultaneous kidney pancreas transplantation; Thymoglobulin

Indexed keywords

BASILIXIMAB; CREATININE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ABSCESS; ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETIC FOOT; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PANCREAS TRANSPLANTATION; LENGTH OF STAY; LEUKOCYTE COUNT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS FUNCTION; PARVOVIRUS INFECTION; POLYOMAVIRUS INFECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK FACTOR; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; PANCREAS TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80054998421     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182313e4f     Document Type: Article

References (18)

1. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1, 000 pancreas transplants at a single institution. Ann Surg 2001; 233: 463.
2. Forsythe JLR. Transplantation. 4th ed. Edinburgh: Saunders Elsevier 2009.
3. Ginns LC, Cosimi AB, Morris PJ. Transplantation. Malden, MA: Blackwell Science 1999.
4. OPTN/SRTR Data as of May 1, 2008.
5. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
6. International Pancreas Transplant Registry. Minneapolis, MN: Department of Surgery, University of Minnesota; vol. 16 2004. Available at: http://www.iptr.umn.edu/annual-reports/home.html. Accessed October 10, 2011.
7. Hesse UJ, Troisi R, Jacobs B, et al. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000; 14(4 Pt 1): 340.
8. Chow FY, Polkinghorne K, Saunder A, et al. Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreasrenal transplantation. Nephrology (Carlton) 2003; 8: 212.
9. Zhang R, Florman S, Devidoss S, et al. A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am J Transplant 2007; 7: 1815.
10. Kaufman DB, Leventhal JR, Gallon LG, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-Long-term results. Am J Transplant 2006; 6: 331.
11. Tanchanco R, Krishnamurthi V, Winans C, et al. Beneficial outcomes of a steroid-free regimen with thymoglobulin induction in pancreaskidney transplantation. Transplant Proc 2008; 40: 1551.
12. Humar A, Khwaja K, Ramcharan T, et al. Chronic rejection: The next major challenge for pancreas transplant recipients. Transplantation 2003; 76: 918.
13. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The 'ReSpECT' study. Am J Transplant 2009; 9: 327.
14. Cattral MS, Bigam DL, Hemming AW, et al. Portal venous and enteric exocrine drainage versus systemic venous and bladder exocrine drainage of pancreas grafts: Clinical outcome of 40 consecutive transplant recipients. Ann Surg 2000; 232: 688.
15. Martin X, Petruzzo P, Dawahra M, et al. Effects of portal versus systemic venous drainage in kidney-pancreas recipients. Transpl Int 2000; 13: 64.
16. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
17. Drachenberg CB, Papadimitriou JC, Klassen DK, et al. Evaluation of pancreas transplant needle biopsy: Reproducibility and revision of histologic grading system. Transplantation 1997; 63: 1579.
18. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: Five-year experience. Ann Surg 2009; 250: 187.